SARS-CoV-2与登革病毒间潜在抗原交叉反应性
该研究分析了55例SARS-CoV-2感染者的临床数据和血清样本,用登革侧流快速检测和ELISA评估登革血清学状态,并在95例登革患者中检测SARS-CoV-2血清学,辅以计算机蛋白质结构分析。结果显示COVID-19患者中登革快速检测阳性率达21.8%,登革患者中SARS-CoV-2血清学阳性/可疑达22%,提示两种病毒间可能存在交叉反应,可导致血清学假阳性。
要点
- COVID-19患者中登革快速检测阳性率21.8%,健康对照为0(P=2.5E-5)。
- 登革患者中SARS-CoV-2 S蛋白血清学阳性/可疑22%,对照为4%(P=1.6E-4)。
- SARS-CoV-2刺突蛋白HR2结构域与登革包膜蛋白表位可能存在相似性。
核心结论
- 研究结果支持登革病毒与SARS-CoV-2间存在交叉反应,可导致COVID-19患者登革血清学假阳性及登革患者SARS-CoV-2血清学假阳性。
研究设计与样本
- 分析55例SARS-CoV-2感染者的临床数据和血清样本,用登革侧流快速检测和ELISA评估登革血清学。
- 在95例2019年9月前诊断的登革患者中检测SARS-CoV-2 S蛋白血清学,并与102例对照比较。
- 进行计算机蛋白质结构分析以识别表位相似性。
主要发现
- 登革侧流快速检测在55例COVID-19患者中检出12例阳性(21.8%),70例健康对照中0例阳性(P=2.5E-5)。
- 12例阳性包括9例IgM阳性、2例IgG阳性、1例IgM和IgG均阳性。
- 登革ELISA(针对包膜蛋白抗体)在另外2例受试者中阳性。
- 95例登革患者中SARS-CoV-2 S蛋白血清学阳性/可疑21例(22%)(16例IgA,5例IgG),102例对照中4例阳性/可疑(4%)(P=1.6E-4)。
- 计算机分析显示SARS-CoV-2刺突蛋白HR2结构域表位与登革包膜蛋白可能存在相似性。
临床怎么用
- 在COVID-19与登革热共流行地区,应警惕登革血清学假阳性,避免因假阳性结果漏诊COVID-19。
- 反之,登革患者中SARS-CoV-2血清学阳性/可疑也可能为交叉反应,需结合核酸检测等确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronavirus disease 2019 (COVID-19) and dengue fever are difficult to distinguish given shared clinical and laboratory features. Failing to consider COVID-19 due to false-positive dengue serology can have serious implications. We aimed to assess this possible cross-reactivity. METHODS: We analyzed clinical data and serum samples from 55 individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. To assess dengue serology status, we used dengue-specific antibodies by means of lateral-flow rapid test, as well as enzyme-linked immunosorbent assay (ELISA). Additionally, we tested SARS-CoV-2 serology status in patients with dengue and performed in-silico protein structural analysis to identify epitope similarities. RESULTS: Using the dengue lateral-flow rapid test we detected 12 positive cases out of the 55 (21.8%) COVID-19 patients versus zero positive cases in a control group of 70 healthy individuals (P = 2.5E-5). This includes 9 cases of positive immunoglobulin M (IgM), 2 cases of positive immunoglobulin G (IgG), and 1 case of positive IgM as well as IgG antibodies. ELISA testing for dengue was positive in 2 additional subjects using envelope protein directed antibodies. Out of 95 samples obtained from patients diagnosed with dengue before September 2019, SARS-CoV-2 serology targeting the S protein was positive/equivocal in 21 (22%) (16 IgA, 5 IgG) versus 4 positives/equivocal in 102 controls (4%) (P = 1.6E-4). Subsequent in-silico analysis revealed possible similarities between SARS-CoV-2 epitopes in the HR2 domain of the spike protein and the dengue envelope protein. CONCLUSIONS: Our findings support possible cross-reactivity between dengue virus and SARS-CoV-2, which can lead to false-positive dengue serology among COVID-19 patients and vice versa. This can have serious consequences for both patient care and public health.
引用
- Lustig Y, Keler S, Kolodny R, et al. Potential Antigenic Cross-reactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Dengue Viruses. Clin Infect Dis. 2021. PMID: 32797228. doi:10.1093/cid/ciaa1207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。